Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Cybin IRL Limited
- Study ID
- NCT06605105
- Phase
- PHASE3
- Status
- Enrolling By Invitation
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- CYB003 — DRUGCYB003 is a deuterated psilocin analog
Study Details
This is a long- term extension of the double-blind trials APPROACH (CYB003-002) and EMBRACE (CYB003-003). Its aim is to examine the safety and long-term efficacy of CYB003 in participants with MDD.
Key Dates
- Start date
- Jul 18, 2025
- Status verified
- Mar 2026
- Primary completion
- Mar 15, 2028
- Completion
- Mar 15, 2028
Study Design
- Enrollment
- 468 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: CYB003Initial non-responders in CYB003-002 APPROACH and CYB003-003 EMBRACE, or initial responders who later relapse will be eligible to receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. If a participant relapses again, the participant may receive an additional single 16mg of CYB003 (maximum of 3 16mg doses in CYB003-004 EXTEND). Participants will continue on their current antidepressants and receive psychological support throughout the study.
Primary Outcome Measure
Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: Baseline, Day 28, Day 56, Day 84, Day 112, Day 140, Day 168, Day 196, Day 244, Day 252, Day 280, Day 301; additional assessments at Day -15, Day -1, Day 2, Day 10, Day 17, Day 21, Day 23, Day 31, Day 42 if non-response or relapse criteria met ]
Locations (19)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Combined Research Orlando | Phoenix | Arizona | 85022 | - |
| Open Mind Collective / UCSF Medical Center - Mount Zion | San Francisco | California | 94114 | - |
| Mountain View Clinical Research | Denver | Colorado | 80209 | - |
| Starlight Clinical Research | Evergreen | Colorado | 80439 | - |
| Research Centers of America | Hollywood | Florida | 33024 | - |
| K2 Medical Research | Lady Lake | Florida | 32159 | - |
| Segal Trials Center for Psychedelic Research | Lauderhill | Florida | 33319 | - |
| Clinical Neuroscience Solutions, Inc | Orlando | Florida | 32801 | - |
| Atlanta Center For Medical Research | Atlanta | Georgia | 30331 | - |
| Cenexel iResearcvh Atlanta, LLC | Atlanta | Georgia | 30030 | - |
| CenExel iResearch | Savannah | Georgia | 31405 | - |
| Uptown Research Institute | Chicago | Illinois | 60640 | - |
| Psychiatric Medicine Associates, LLC | Skokie | Illinois | 60076 | - |
| Sunstone Medical, PC | Rockville | Maryland | 20850 | - |
| Adams Clinical Boston | Boston | Massachusetts | 02116 | - |
| Adams Clinical | Watertown | Massachusetts | 02472 | - |
| Neurobehavioral Clinical Research | Canton | Ohio | 44720 | - |
| InSite Clinical Research, LLC | DeSoto | Texas | 75115 | - |
| Cedar Clinical Research | Draper | Utah | 84020 | - |
Find similar trials in Phoenix, AZ
By condition
By specialty
Related Studies
- Study of Neuro-Cognitive Correlates of Pediatric Anxiety DisordersPHASE2 · Recruiting · National Institute of Mental Health (NIMH) · Bethesda, Maryland
- Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive DisorderPHASE1 · Recruiting · National Institute of Mental Health (NIMH) · Bethesda, Maryland
- DBS for DepressionRecruiting · Baylor College of Medicine · Dallas, Texas
- Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar DisorderEARLY_PHASE1 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts